Fig 1.
aThe 110,791 patients contributed 392,566 treatment episodes.
Fig 2.
Adverse event (AE) occurrence in the context of distinct treatment episodes [5].
aTreatment episode start date was defined as the date of the initiation of the first antineoplastic agent as part of a treatment regimen. bTreatment episode end date was defined as the first of the following events: discontinuation of the treatment regimen (i.e., a gap of ≥45 days in the use of all agents in the treatment), change in treatment regimen, the end of health plan enrollment, or the end of data availability.
Table 1.
Treatment episodes characteristics.
Table 2.
Prevalence and characteristics of matched treatment episodes by AE.
Fig 3.
Incremental costs per matched treatment episodea—AEs of any severity, within the pooled sample of patients with cancer.
Incremental costs reported as means (95% confidence interval) in US dollars. AE, adverse event; GI, gastrointestinal; CNS, central nervous system. aOnly AEs with ≥ 50 matched treatment episode pairs (with ≥ 100 treatment episodes) were included.
Fig 4.
Incremental costs per matched treatment episodea—severe AEs, within the pooled sample of patients with cancer.
Incremental costs reported as means (95% confidence interval) in US dollars. AEs, adverse events; CNS, central nervous system; GI, gastrointestinal. aOnly severe AEs (grade 3–4) with ≥ 25 matched treatment episode pairs (with ≥ 50 treatment episodes) were included.
Table 3.
Mean incremental costs (in US dollars) per treatment episode—AEs of any severity, stratified by common tumor type (≥6% of selected patients). Each n indicates the number of treatment episodes.
Table 4.
Mean incremental costs (in US dollars) per treatment episode—AEs of any severity in rarer tumor types (<6% of selected patients). Each n indicates the number of episodes.